Mylan said that it would restructure and expected to cut less than 10 percent of its global workforce as it integrates acquisitions. » Read More
By: Anna Robaton
The coming transfer of $30 trillion in assets from baby boomers to their heirs is creating challenges for clients and advisors alike. » Read More
By: Andrew Prokop
Several of Trump's most recent Cabinet picks are in no way outsider populists. In fact, they're all staunch conservatives, Vox reports. » Read More
Rep. Tom Price already has a plan for how to abolish the Affordable Care Act. » Read More
Hospitals that benefited under Obamacare likely will see a reversal of fortune and there are new risks for already struggling insurers.
President-elect Donald Trump has been making changes to his governing agenda following his election victory.
One anti-anxiety drug, Ativan, had an average unit cost increase of a stunning 1,264 percent between 2014 and 2015 for Medicaid.
At the New York Times' DealBook Conference, CNBC's Andrew Ross Sorkin speaks with Aetna CEO Mark Bertolini about health insurance and the possibility of the Trump administration repealing Obamacare.
Jon Reinish, Democratic strategist, and Former Lt. Gov. Betsy McCaughey, (R-N.Y.), provide their thoughts on how Donald Trump will likely govern, and act on issues such as Obamacare, fracking and regulations.
Drugmaker Mylan may have overcharged hospitals that serve significant numbers of poor people for lifesaving anti-allergy devices.
The West Virginia attorney general says Mylan could be liable for more than the $465 million the company agreed to pay.
Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims.
Federal health officials are looking to get more uninsured and younger adults to sign up for Obamacare.
Chris Raymond, Raymond James analyst, discusses how to trade the biotech sell-off amid election season.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.
Mylan has been under fire for months over sky-high price hikes of anti-allergy EpiPen devices.
CNBC's Meg Tirrell reports the latest on Mylan's EpiPen classification and rebate through Medicaid.
Mylan's share of revenue from EpiPen due to Medicare and Medicaid more than doubled from 2011-2015.
A report also found similar reductions in the uninsured rate in urban and rural areas under Obamacare.
Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid.